Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...
The Swiss healthtech startup’s patented multi-tissue platform is designed to improve the speed, safety, and human relevance ...
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹?TP). The ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance.
Genetic treatments could be the key to unlocking some rare diseases. But bringing these medicines to patients involves ...
Bacterial Conjunctivitis Drugs Market is expected to reach US$ 4.9 Billion by 2036, Driven by Increasing Prevalence of Eye ...
After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...
SwineTech co-founder Matthew Rooda recalls how he blended animal agriculture and health care technology to reduce piglet ...
REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback